WB, ChIP, ChIP-seq, C&R
H M R Mk
Endogenous
74, 64
Rabbit IgG
#Q15326
10771
Product Information
Product Usage Information
The CUT&RUN dilution was determined using CUT&RUN Assay Kit #86652.
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Chromatin IP | 1:50 |
Chromatin IP-seq | 1:50 |
CUT&RUN | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro430 of human ZMYND11/BS69 protein.
Background
ZMYND11, also commonly referred to as BS69, is a ubiquitous chromatin reader protein that recognizes tri-methyl histone H3 lysine 36 (H3K36me3) and acts as a transcriptional repressor. It contains several domains associated with chromatin reader proteins, including an N-terminal PHD finger, a bromodomain, a PWWP domain, and a C-terminal MYND domain (1), and it shares a similar domain organization with its homolog protein ZMYND8/RACK7 (2). ZMYND11 specifically recognizes and binds to H3K36me3 modification sites on histone variant H3.3 (but not H3.1 nor H3.2), and modulates RNA Polymerase II-mediated elongation (3). ZMYND11 colocalizes with areas of high gene expression and associates with transcription factors such as E1A, MGA, Ets-2, c-Myb, and B-Myb (4). Due to its ability to repress oncogene expression, ZMYND11 is considered to be a tumor suppressor and is found to be downregulated, mutated, translocated, and show copy number variations in many types of cancer. Low levels of ZMYND11 correlate with poor prognosis in breast cancer, whereas its overexpression suppresses cancer cell growth in vivo and tumor formation in mice (3). Translocation of ZMYND11-MBTD1 is associated with acute myeloid leukemia (AML) (5-6). Copy number variations have been associated with multiple hematological disorders, including AML, acute lymphoblastic leukemia (ALL), and multiple myeloma (MM), among others (7). Translocations and mutations of ZMYND11 have also been found to be associated with autism and other neuropsychiatric and intellectual disabilities (7).
- Wang, J. et al. (2014) Cell Res 24, 890-3.
- Ansieau, S. and Sergeant, A. (2003) Pathol Biol (Paris) 51, 397-9.
- Wen, H. et al. (2014) Nature 508, 263-8.
- Velasco, G. et al. (2006) J Biol Chem 281, 16546-50.
- De Braekeleer, E. et al. (2014) Leuk Lymphoma 55, 1189-90.
- Yamamoto, K. et al. (2018) Leuk Lymphoma, 1-5.
- Yang, H. et al. (2010) Ann Hematol 89, 959-64.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting ChIP: Chromatin IP ChIP-seq: Chromatin IP-seq C&R: CUT&RUN
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.